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Background. Recently, pathogenic serum immunoglobulin G (IgG) autoantibodies tomyelin oligodendrocyte glycoprotein (MOG)
have been detected in a subgroup of patients with central nervous system (CNS) demyelination, including in patients with myelitis.
Relatively little is known so far about leptomeningeal involvement in MOG-IgG-positive myelitis. Findings. We report the case
of a 30-year-old previously healthy woman presenting with longitudinally extensive transverse myelitis and tetraparesis, in whom
both the leptomeningeal barrier and the blood-brain barrier (BBB) were altered, as demonstrated by gadolinium-enhanced MRI
during relapse. Blood samples taken at onset and four years laterwere retrospectively found positive forMOG-IgG.Conclusion. Our
findings demonstrate that spinal leptomeningeal enhancement (LME) can occur inMOG-IgG-positive encephalomyelitis (EM) and
may accompany intraparenchymal BBB breakdown.
1. Introduction
Pathogenic immunoglobulinG (IgG) autoantibodies directed
to myelin oligodendrocyte glycoprotein (MOG), an oligo-
dendrocytic protein localized to the outer surface of the
myelin sheaths, have recently been identified in patients with
inflammatory CNS demyelination [1–6]. This discovery has
led to the recognition of a new disease entity, now often
referred to as “MOG encephalomyelitis” (MOG-EM) [2].
Phenotypically, MOG-EM may present as optic neuritis
(ON), (often longitudinally extensive) transverse myelitis,
brainstem encephalitis, encephalitis, or any combination
of these syndromes and, especially in children, as acute
demyelinating encephalomyelitis (ADEM) [3–6].
Myelitis is often associated with leptomeningeal (pia-
arachnoid) contrast enhancement (LME). LME is a sign of
leptomeningeal barrier impairment and leakage of contrast
agent into the subarachnoid space. Understanding LME
patterns may help in the differential diagnosis of the various
forms of myelitis [7–10]. So far, little is known about LME in
MOG-IgG-positive myelitis.
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Figure 1: Spinal cord MRI. Sagittal gadolinium-enhanced T1-weighted images with fat saturation showing linear leptomeningeal thickening
and enhancement (a) and intramedullary parenchymal patchy enhancement (b), correlating with diffuse T2-weighted hyperintense signal
increase extending from C2 toTh3 (c).
2. Case Report
A 30-year-old woman with no previous history of systemic
inflammatory disease or neoplastic diseases developed loss
of vision in the left eye and two days later in the right eye
due to acute ON, followed by tetraparesis two weeks later.
Spinal cord MRI obtained prior to treatment revealed LME,
intraparenchymal contrast enhancement corresponding to
the site of LME, and longitudinal extensive transversemyelitis
(LETM) extending from C2 toTh3 (Figure 1).
Cerebral MRI was normal. Cerebrospinal fluid contained
122 leukocytes/mm3 with polymorphonuclear predomi-
nance; oligoclonal bands were not determined. Aquaporin-
4 (AQP4)-IgG was negative. Accordingly, seronegative neu-
romyelitis optica was suspected by that time. Follow-up MRI
demonstrated resolution of LME four months later.
Retrospective testing by means of two cell-based assays
employing fixed and live HEK293 cells, respectively, trans-
fected with full-length humanMOG revealed the presence of
MOG-IgG antibodies in a serum sample taken at onset [1, 2].
MOG-IgG seropositivity was confirmed in a second sample
taken four years later.
3. Discussion
Inflammation in demyelinating diseases of the CNS is com-
monly associated with blood-brain barrier (BBB) disruption.
Leptomeningeal involvement has recently been recognized
as an important feature in multiple sclerosis pathogenesis
[8]. LME has also been observed in AQP4-IgG-positive neu-
romyelitis optica spectrumdisorder [9, 10].Here, we present a
case ofMOG encephalomyelitis (MOG-EM) [2] with a longi-
tudinally extensive demyelinating spinal cord lesion in which
the blood-CNS barriers were disrupted, as demonstrated by
gadolinium-enhanced MRI. Our findings demonstrate that
spinal cord LME may occur also in MOG-EM, one of the
most important differential diagnoses of MS. Notably, LME,
which indicates an abnormally permeable leptomeningeal-
blood barrier, was accompanying intraparenchymal BBB
breakdown during an attack of acute myelitis, as visualised by
contrast enhancement on T1-weighted imaging. This finding
suggests thatmeningeal inflammationmayhave occurred as a
bystander reaction followingMOG-IgG-related parenchymal
inflammation associated with subpial demyelination. Lesions
involving the peripheral portions of the spinal cord indeed
occur in a substantial number of cases of MOG-IgG-positive
myelitis, as has recently been shown [3]. Similarly, corti-
cal brain lesions have been described in MOG-EM, some
of which were associated with LME [3, 11], and patients
with MOG-IgG-positive ON may commonly present with
perioptic contrast enhancement [3]. Future studies should
systematically assess the presence of LME in MOG-IgG-
related myelitis as well as its potential value in discriminating
MOG-EM and other demyelinating diseases affecting the
spinal cord.




CNS: Central nervous system
CSF: Cerebrospinal fluid
IgG: Immunoglobulin G
LETM: Longitudinal extensive transverse myelitis
LME: Leptomeningeal enhancement
MOG: Myelin oligodendrocyte glycoprotein
MRI: Magnetic resonance imaging
ON: Optic neuritis.
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